Where Discovery Begins
H_IL-5RA TF-1 Cell Line
Cat. No.
GM-C46352
Size
2 vial
Quote
Description
Data Display
Specifications
Materials
Cell Culture
Related products
Description
IL-5 is a 115-aa (human) / 133-aa (mouse) Th2 cytokine of the hematopoietic family. Unlike IL-3 and GM-CSF, it is an active homodimer. The IL-5 receptor (IL-5R), a type I cytokine receptor, is a heterodimer: the α subunit binds IL-5 (confers specificity), while the β subunit mediates signaling without binding IL-5.

IL-5 is linked to allergic diseases (e.g., rhinitis, asthma), where eosinophils play a key pathogenic role. Mepolizumab, a humanized mAb targeting IL-5, blocks IL-5/IL-5Rα binding via steric hindrance, inhibiting IL-5Rα/βc complex formation and JAK2-STAT5 signaling. It is used for severe eosinophilic asthma, EGPA, HES, and CRSwNP.

IL-5RA (CD125) specifically binds IL-5 but lacks an independent signaling domain; it must assemble with the βc subunit (CD131) to initiate downstream signaling. Wild-type TF-1 cells express endogenous βc but lack IL-5RA, thus failing to proliferate in response to IL-5.

H_IL-5RA TF-1 Cell Line is a clonal stable BaF3 cell line constructed using lentiviral technology,constitutive expression of the Human IL-5RA gene. Can be used for the development and
validation of related drugs.
IL-5 is a 115-aa (human) / 133-aa (mouse) Th2 cytokine of the hematopoietic family. Unlike IL-3 and GM-CSF, it is an active homodimer. The IL-5 receptor (IL-5R), a type I cytokine receptor, is a heterodimer: the α subunit binds IL-5 (confers specificity), while the β subunit mediates signaling without binding IL-5.

IL-5 is linked to allergic diseases (e.g., rhinitis, asthma), where eosinophils play a key pathogenic role. Mepolizumab, a humanized mAb targeting IL-5, blocks IL-5/IL-5Rα binding via steric hindrance, inhibiting IL-5Rα/βc complex formation and JAK2-STAT5 signaling. It is used for severe eosinophilic asthma, EGPA, HES, and CRSwNP.

IL-5RA (CD125) specifically binds IL-5 but lacks an independent signaling domain; it must assemble with the βc subunit (CD131) to initiate downstream signaling. Wild-type TF-1 cells express endogenous βc but lack IL-5RA, thus failing to proliferate in response to IL-5.

H_IL-5RA TF-1 Cell Line is a clonal stable BaF3 cell line constructed using lentiviral technology,constitutive expression of the Human IL-5RA gene. Can be used for the development and
validation of related drugs.
Data Display
Signaling Pathway
Cell proliferation assay. The H_IL-5RA TF-1 Cell Line (Cat. GM-C46352) at a density of 5000 cells/well (96-well format) was treated with serial dilutions of Human IL-5 Protein; His Tag (Cat. GM-88539RP) in assay buffer (RPMI 1640+10% FBS+1% P.S) for 96 hours. The firefly luciferase activity was measured the GMTiter™ Luminescent Cell Viability Assay (Cat. GM-040504).
Expression
H_IL-5RA TF-1 Cell Line (Cat. GM-C46352) was determined by flow cytometry using Anti-IL-5R hIgG1 Antibody(Cat. GM-46851AB).
Specifications
Cat. No GM-C46352
Product H_IL-5RA TF-1 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium RPMI 1640+10% FBS+1% P.S
Growth medium RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin
Note None
Freezing Medium 90% FBS+10% DMSO
Growth properties Suspension
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Cat. No GM-C46352
Product H_IL-5RA TF-1 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium RPMI 1640+10% FBS+1% P.S
Growth medium RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin
Note None
Freezing Medium 90% FBS+10% DMSO
Growth properties Suspension
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Materials
Reagent Ordering Information
RPMI 1640 gibco/C11875500BT
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Recombinant Human GM-CSF Novoprotein/C003
Puromycin Genomeditech/GM-040401
Human IL-5 Protein; His Tag Genomeditech/GM-88539RP
Anti-IL-5R hIgG1 Antibody Genomeditech/GM-46851AB
GMTiter™ Luminescent Cell Viability Assay 细胞活力检测试剂盒 Genomeditech/GM-040504
Reagent Ordering Information
RPMI 1640 gibco/C11875500BT
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Recombinant Human GM-CSF Novoprotein/C003
Puromycin Genomeditech/GM-040401
Human IL-5 Protein; His Tag Genomeditech/GM-88539RP
Anti-IL-5R hIgG1 Antibody Genomeditech/GM-46851AB
GMTiter™ Luminescent Cell Viability Assay 细胞活力检测试剂盒 Genomeditech/GM-040504
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend the cell pellet using the recommended complete medium and adjust the viable cell density to 4-6E5 cells/mL. Then dispense the suspension into an appropriate culture flask and initially place the flask in an upright position after thawing.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 3E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin

Approximately 48 - 72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics.

a)          This cell is a human erythroid leukemia cell, lymphoblast, growing in suspension.

b)         In the suspension, they appear as large, single, round cells. Cells shed a large accumulation of cytoplasmic granules in the culture, which should not be confused with bacteria!

c)          When the cell density reaches 1-1.2E6 cells/mL, perform a 1:2 to 1:3 split, ensuring subculturing every other day. It is essential to perform a full-volume centrifugation and medium replacement during passaging. Do not let the density exceed 1.2E6 cells/mL. It is recommended to use T-25 flasks for subculturing, and you can control the cell density for subculturing by counting.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 4E5 and 6E5 viable cells/mL.

Medium Renewal: Every other day

Notes

a)          To minimize the presence of cytoplasmic granules, it is essential to passage the cells every other day when the cell density reaches 1-1.2E6 cells/mL. During passaging, perform a complete centrifugation and replace the culture medium to ensure appropriate cell density and cytokine concentration. Failure to do so may promote the growth of factor-independent subclones.

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend the cell pellet using the recommended complete medium and adjust the viable cell density to 4-6E5 cells/mL. Then dispense the suspension into an appropriate culture flask and initially place the flask in an upright position after thawing.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 3E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin

Approximately 48 - 72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics.

a)          This cell is a human erythroid leukemia cell, lymphoblast, growing in suspension.

b)         In the suspension, they appear as large, single, round cells. Cells shed a large accumulation of cytoplasmic granules in the culture, which should not be confused with bacteria!

c)          When the cell density reaches 1-1.2E6 cells/mL, perform a 1:2 to 1:3 split, ensuring subculturing every other day. It is essential to perform a full-volume centrifugation and medium replacement during passaging. Do not let the density exceed 1.2E6 cells/mL. It is recommended to use T-25 flasks for subculturing, and you can control the cell density for subculturing by counting.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 4E5 and 6E5 viable cells/mL.

Medium Renewal: Every other day

Notes

a)          To minimize the presence of cytoplasmic granules, it is essential to passage the cells every other day when the cell density reaches 1-1.2E6 cells/mL. During passaging, perform a complete centrifugation and replace the culture medium to ensure appropriate cell density and cytokine concentration. Failure to do so may promote the growth of factor-independent subclones.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
H_IL-5RA TF-1 Cell Line
H_IL-5RA TF-1 Cell Line
Cat. No.
GM-C46352
Size
2 vial
Quote
Description
Data Display
Specifications
Materials
Cell Culture
Related products
Description
IL-5 is a 115-aa (human) / 133-aa (mouse) Th2 cytokine of the hematopoietic family. Unlike IL-3 and GM-CSF, it is an active homodimer. The IL-5 receptor (IL-5R), a type I cytokine receptor, is a heterodimer: the α subunit binds IL-5 (confers specificity), while the β subunit mediates signaling without binding IL-5.

IL-5 is linked to allergic diseases (e.g., rhinitis, asthma), where eosinophils play a key pathogenic role. Mepolizumab, a humanized mAb targeting IL-5, blocks IL-5/IL-5Rα binding via steric hindrance, inhibiting IL-5Rα/βc complex formation and JAK2-STAT5 signaling. It is used for severe eosinophilic asthma, EGPA, HES, and CRSwNP.

IL-5RA (CD125) specifically binds IL-5 but lacks an independent signaling domain; it must assemble with the βc subunit (CD131) to initiate downstream signaling. Wild-type TF-1 cells express endogenous βc but lack IL-5RA, thus failing to proliferate in response to IL-5.

H_IL-5RA TF-1 Cell Line is a clonal stable BaF3 cell line constructed using lentiviral technology,constitutive expression of the Human IL-5RA gene. Can be used for the development and
validation of related drugs.

IL-5 is a 115-aa (human) / 133-aa (mouse) Th2 cytokine of the hematopoietic family. Unlike IL-3 and GM-CSF, it is an active homodimer. The IL-5 receptor (IL-5R), a type I cytokine receptor, is a heterodimer: the α subunit binds IL-5 (confers specificity), while the β subunit mediates signaling without binding IL-5.

IL-5 is linked to allergic diseases (e.g., rhinitis, asthma), where eosinophils play a key pathogenic role. Mepolizumab, a humanized mAb targeting IL-5, blocks IL-5/IL-5Rα binding via steric hindrance, inhibiting IL-5Rα/βc complex formation and JAK2-STAT5 signaling. It is used for severe eosinophilic asthma, EGPA, HES, and CRSwNP.

IL-5RA (CD125) specifically binds IL-5 but lacks an independent signaling domain; it must assemble with the βc subunit (CD131) to initiate downstream signaling. Wild-type TF-1 cells express endogenous βc but lack IL-5RA, thus failing to proliferate in response to IL-5.

H_IL-5RA TF-1 Cell Line is a clonal stable BaF3 cell line constructed using lentiviral technology,constitutive expression of the Human IL-5RA gene. Can be used for the development and
validation of related drugs.

Data Display
Signaling Pathway
Cell proliferation assay. The H_IL-5RA TF-1 Cell Line (Cat. GM-C46352) at a density of 5000 cells/well (96-well format) was treated with serial dilutions of Human IL-5 Protein; His Tag (Cat. GM-88539RP) in assay buffer (RPMI 1640+10% FBS+1% P.S) for 96 hours. The firefly luciferase activity was measured the GMTiter™ Luminescent Cell Viability Assay (Cat. GM-040504).
Expression
H_IL-5RA TF-1 Cell Line (Cat. GM-C46352) was determined by flow cytometry using Anti-IL-5R hIgG1 Antibody(Cat. GM-46851AB).
Specifications
Cat. No GM-C46352
Product H_IL-5RA TF-1 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium RPMI 1640+10% FBS+1% P.S
Growth medium RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin
Note None
Freezing Medium 90% FBS+10% DMSO
Growth properties Suspension
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Cat. No GM-C46352
Product H_IL-5RA TF-1 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium RPMI 1640+10% FBS+1% P.S
Growth medium RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin
Note None
Freezing Medium 90% FBS+10% DMSO
Growth properties Suspension
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Materials
Reagent Ordering Information
RPMI 1640 gibco/C11875500BT
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Recombinant Human GM-CSF Novoprotein/C003
Puromycin Genomeditech/GM-040401
Human IL-5 Protein; His Tag Genomeditech/GM-88539RP
Anti-IL-5R hIgG1 Antibody Genomeditech/GM-46851AB
GMTiter™ Luminescent Cell Viability Assay 细胞活力检测试剂盒 Genomeditech/GM-040504
Reagent Ordering Information
RPMI 1640 gibco/C11875500BT
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Recombinant Human GM-CSF Novoprotein/C003
Puromycin Genomeditech/GM-040401
Human IL-5 Protein; His Tag Genomeditech/GM-88539RP
Anti-IL-5R hIgG1 Antibody Genomeditech/GM-46851AB
GMTiter™ Luminescent Cell Viability Assay 细胞活力检测试剂盒 Genomeditech/GM-040504
Cell Culture

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend the cell pellet using the recommended complete medium and adjust the viable cell density to 4-6E5 cells/mL. Then dispense the suspension into an appropriate culture flask and initially place the flask in an upright position after thawing.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 3E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin

Approximately 48 - 72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics.

a)          This cell is a human erythroid leukemia cell, lymphoblast, growing in suspension.

b)         In the suspension, they appear as large, single, round cells. Cells shed a large accumulation of cytoplasmic granules in the culture, which should not be confused with bacteria!

c)          When the cell density reaches 1-1.2E6 cells/mL, perform a 1:2 to 1:3 split, ensuring subculturing every other day. It is essential to perform a full-volume centrifugation and medium replacement during passaging. Do not let the density exceed 1.2E6 cells/mL. It is recommended to use T-25 flasks for subculturing, and you can control the cell density for subculturing by counting.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 4E5 and 6E5 viable cells/mL.

Medium Renewal: Every other day

Notes

a)          To minimize the presence of cytoplasmic granules, it is essential to passage the cells every other day when the cell density reaches 1-1.2E6 cells/mL. During passaging, perform a complete centrifugation and replace the culture medium to ensure appropriate cell density and cytokine concentration. Failure to do so may promote the growth of factor-independent subclones.

Cell Recovery

Recovery Medium: RPMI 1640+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium. And spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend the cell pellet using the recommended complete medium and adjust the viable cell density to 4-6E5 cells/mL. Then dispense the suspension into an appropriate culture flask and initially place the flask in an upright position after thawing.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 3E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: RPMI 1640+10% FBS+1% P.S+2 ng/mL GM-CSF+0.25 μg/mL Puromycin

Approximately 48 - 72 hours after the initial thawing, the cells can be passaged for the first time. After this initial passage, the culture medium can be adjusted to growth medium supplemented with antibiotics.

a)          This cell is a human erythroid leukemia cell, lymphoblast, growing in suspension.

b)         In the suspension, they appear as large, single, round cells. Cells shed a large accumulation of cytoplasmic granules in the culture, which should not be confused with bacteria!

c)          When the cell density reaches 1-1.2E6 cells/mL, perform a 1:2 to 1:3 split, ensuring subculturing every other day. It is essential to perform a full-volume centrifugation and medium replacement during passaging. Do not let the density exceed 1.2E6 cells/mL. It is recommended to use T-25 flasks for subculturing, and you can control the cell density for subculturing by counting.

Subcultivation Ratio: Maintain cultures at a cell concentraion between 4E5 and 6E5 viable cells/mL.

Medium Renewal: Every other day

Notes

a)          To minimize the presence of cytoplasmic granules, it is essential to passage the cells every other day when the cell density reaches 1-1.2E6 cells/mL. During passaging, perform a complete centrifugation and replace the culture medium to ensure appropriate cell density and cytokine concentration. Failure to do so may promote the growth of factor-independent subclones.

Contact
Us
Message Inquiry
reset
submit
Message
Message Inquiry
reset
submit